1.
Rhonda L Harmon and Paul H Sugarbaker,
Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer,
Int Semin Surg Oncol.
2005; 2: 3.
2.
Chukwuemeka U.
Ihemelandu et al,
Management of Peritoneal Carcinomatosis from Colorectal Cancer,
Semin Oncol.
2011; 38(4): 568–575.
3.
Emily A.
Aherne et al,
What the Radiologist Should Know About Treatment of Peritoneal Malignancy, American Journal of Radiology,
March 2017,
Volume 208,
Number 3
4.Chandramohan A,
Thrower A,
Smith SA,
et al.
“PAUSE”: a method for communicating radiological extent of peritoneal malignancy.
Clin Radiol.
2017 72;11: 972-980.
5.Sanket S.
Mehta et al,
Cytoreductive Surgery and Peritonectomy Procedures,
Indian J Surg Oncol.
2016 Jun; 7(2): 139–151.
6.S.
J.
Valle et al,
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology,
Drugs and Bidirectional Chemotherapy,
Indian J Surg Oncol.
2016 Jun; 7(2): 152–159.
7.Giorgi Nadiradze et al,
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis,
J Gastrointest Surg.
2016; 20: 367–373.
8.
Ramy Girshally et al,
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy,
World Journal of Surgical Oncology.
201614:253.
9.Antoni Llueca et al,
Prognostic value of peritoneal cancer index in primary advanced ovarian cancer,
European journal of surgical oncolog,
January 2018,
Volume 44,
Issue 1,
Pages 163–16.
10.Geert A Simkens et al,
Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer,
Cancer Manag Res.
2017; 9: 259–266.
11.Chirag M.
Patel et al,
CT,
MRI and PET imaging in peritoneal malignancy,
Cancer Imaging.
2011; 11(1): 123–139.
12.
Russell N.
Low,
Preoperative and surveillance MR imaging of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy,
J Gastrointest Oncol.
2016 Feb; 7(1): 58–71.